Evaluation of CD64 Index in HBV and in Chronic HCV Infections
- 1 Tropical Medicine and Gastroenterology Department, Qena Faculty of Medicine, South Valley University, Qena, Egypt
- 2 Clinical and Chemical Pathology Department, Qena Faculty of Medicine, South Valley University, Qena, Egypt
- 3 Tropical Medicine and Gastroenterology Department, Qena Faculty of Medicine, South Valley University, Qena, Egypt
- 4 Oncological Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
- 5 Internal Medicine Department, Division of Gastroenterology, Assiut Faculty of Medicine, Assiut, Egypt
Abstract
Background and aims: CD64 [Fc gamma receptor 1 (FcγRI)] is a promising biomarker used in predicting severe bacterial infection. The study was designed to assess their level in all stages of HBV infection and in chronic HCV infection before and after treatment with direct acting antiviral therapy as a possible biomarker of inflammation. Patients and methods: A case-control study was conducted, 50 patients with different disease stages of HBV infection (10 acute, 15 chronic hepatitis, 15 liver cirrhosis (LC) and 10 with hepatocellular carcinoma (HCC)), twenty patients with chronic HCV and 15 as a control group. Laboratory and imaging studies were evaluated. The levels of CD64 expressions in peripheral blood and CD64 Index were measured for all patients by flowcytometry using fluorescein isothiocyanate (FITC)-conjugated anti-CD64 monoclonal antibody. Results: The levels of CD64 expressions in peripheral blood and CD64 index were significantly higher in patients with HBV and HCV than in control group (P value = 0.01, 0.01 and 0.000, 0.000 respectively). They were increased significantly with disease progression in patients with HBV infection, acute hepatitis B infection showed the highest values. Their levels were significantly decreased in patients with HCV infection post treatment than before treatment. Conclusions: The levels of CD64 expressions in peripheral blood and CD64 index are considered good biomarkers of inflammation in viral hepatitis both B and C and could detect disease progression and also suppression of inflammation after antiviral therapy.
- World Health Organization (WHO) Hepatitis, C. (2011) Fact Sheet Number 164 http://www.who.int/mediacentre/factsheets/fs164/en/index.html
- Lavanchy, D. (2011) Evolving Epidemiology of Hepatitis C Virus. Clinical Microbiology and Infection, 17, 107-115. https://doi.org/10.1111/j.1469-0691.2010.03432.x
- van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. (2012) Association between Sustained Virological Response and All-Cause Mortality among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis. The Journal of the American Medical Association, 308, 2584-2593. https://doi.org/10.1001/jama.2012.144878
- Arase, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Kawamura, Y., Akuta, N., et al. (2013) Effect of Type 2 Diabetes on Risk for Malignancies Includes Hepatocellular Carcinoma in Chronic Hepatitis C. Hepatology, 57, 964-973. https://doi.org/10.1002/hep.26087
- Ott, J.J., Stevens, G.A., Groeger, J. and Wiersma, S.T. (2012) Global Epidemiology of Hepatitis B Virus Infection: New Estimates of Age-Specific HBsAg Seroprevalence and Endemicity. Vaccine, 30, 2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116
- Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E. and Margolis, H.S. (2005) Amathematical Model to Estimate Global Hepatitis B Disease Burden and Vaccination Impact. International Journal of Epidemiology, 34, 1329-1339. https://doi.org/10.1093/ije/dyi206
- Papatheodoridis, G.V., Manolakopoulos, S., Liaw, Y.F. and Lok, A. (2012) Follow-Up Andindications for Liver Biopsy in HBeAg-Negative Chronic Hepatitis B Virus Infection with Persistently Normal ALT: A Systematic Review. Journal of Hepatology, 57, 196-202. https://doi.org/10.1016/j.jhep.2011.11.030
- Raimondo, G., Allain, J.P., Brunetto, M.R., Buendia, M.A., Chen, D.S., Colombo, M., et al. (2008) Statements from the Taormina Expert Meeting on Occult Hepatitis B Virus Infection. Journal of Hepatology, 49, 652-657. https://doi.org/10.1016/j.jhep.2008.07.014
- Fattovich, G., Stroffolini, T., Zagni, I. and Donato, F. (2004) Hepatocellular Carcinoma Incirrhosis: Incidence and Risk Factors. Gastroenterology, 127, S35-S50. https://doi.org/10.1053/j.gastro.2004.09.014
- Feng, H., Yin, J., Han, Y.P., Zhou, X.Y. and Zhang, G.X. (2015) Lymphocyte CD64 Increased in Patients with Chronic HBV Infection. International Journal of Clinical and Experimental Medicine, 8, 10746-10752.
- Icardi, M., Erickson, Y., Kilborn, S., Stewart, B., Grief, B. and Scharnweber, G. (2009) CD64 Index Provides Simple and Predictive Testing for Detection and Monitoring of Sepsis and Bacterial Infection in Hospital Patients. Journal of Clinical Microbiology, 47, 3914-3919. https://doi.org/10.1128/JCM.00628-09